Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Trial Profile

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Tisagenlecleucel (Primary)
  • Indications Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
    • 23 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2019.
    • 06 Jun 2017 Results assessing the effect of pembrolizumab in combination with (CAR) T cells in patients with relapsed B-ALL from NCT02374333 and NCT02906371 trials (n=4), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top